AstraZeneca plc (LON:AZN) has received a consensus recommendation of “Hold” from the twenty-two brokerages that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is GBX 6,336.82 ($82.80).
A number of brokerages have recently weighed in on AZN. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a research note on Friday, March 29th. Jefferies Financial Group reiterated a “hold” rating on shares of AstraZeneca in a research note on Thursday, March 14th. Goldman Sachs Group reiterated a “sell” rating on shares of AstraZeneca in a research note on Monday, March 18th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, March 11th. Finally, Deutsche Bank reiterated a “buy” rating and set a GBX 6,900 ($90.16) target price on shares of AstraZeneca in a research note on Tuesday, February 26th.
Shares of AstraZeneca stock traded down GBX 30 ($0.39) on Friday, reaching GBX 5,988 ($78.24). The stock had a trading volume of 2,827,378 shares, compared to its average volume of 2,310,000. The company has a current ratio of 0.96, a quick ratio of 0.71 and a debt-to-equity ratio of 136.31. AstraZeneca has a fifty-two week low of GBX 4,874.50 ($63.69) and a fifty-two week high of GBX 6,540 ($85.46). The stock has a market capitalization of $78.55 billion and a price-to-earnings ratio of 35.22.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.